Ekso Bionics Holdings Inc. logo

Ekso Bionics Holdings Inc. (0IFR)

Delisted
Want to track 0IFR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

0IFR is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).
Ekso Bionics Announces New Effective Date of Reverse Stock Split

Ekso Bionics Announces New Effective Date of Reverse Stock Split

SAN RAFAEL, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it has updated the effective date of its reverse stock split of shares of its common stock at a ratio of 1-for-15 to June 2, 2025 at 12:01 a.m., Pacific time, rather than the previously disclosed effective date of May 27, 2025 at 12:01 a.m. Pacific time. The Company's common stock will open for trading on The Nasdaq Capital Market on June 2, 2025 on a split-adjusted basis under the existing symbol “EKSO”. The Company's common stock will trade under a new CUSIP number 282644 400 upon the effectiveness of the reverse stock split.

Globenewswire | 1 month ago
Ekso Bionics Announces Reverse Stock Split

Ekso Bionics Announces Reverse Stock Split

SAN RAFAEL, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it will effect a reverse stock split of shares of its common stock at a ratio of 1-for-15, effective as of May 27, 2025 at 12:01 a.m. Pacific time. The Company's common stock will open for trading on The Nasdaq Capital Market on May 27, 2025 on a split-adjusted basis under the existing symbol “EKSO”. The Company's common stock will trade under a new CUSIP number 282644 400 upon the effectiveness of the reverse stock split.

Globenewswire | 1 month ago
Ekso Bionics Holdings, Inc. (EKSO) Q1 2025 Earnings Call Transcript

Ekso Bionics Holdings, Inc. (EKSO) Q1 2025 Earnings Call Transcript

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Stephen Kilmer - IR Jerome Wong - Chief Financial Officer Scott Davis - Chief Executive Officer Conference Call Participants Ben Haynor - Lake Street Capital Markets Swayampakula Ramakanth - H.C. Wainwright Operator Greetings, and welcome to the Ekso Bionics First Quarter 2025 Financial Results Conference Call.

Seekingalpha | 2 months ago

Ekso Bionics Holdings Inc. Profile

Medical - Instruments & Supplies Industry
Healthcare Sector
Scott G. Davis CEO
LSE Exchange
US2826444000 ISIN
US Country
61 Employees
- Last Dividend
2 Jun 2025 Last Split
16 Jan 2014 IPO Date

Overview

Ekso Bionics Holdings, Inc. is a pioneer in the field of robotic exoskeletons, focusing on designing, developing, selling, and renting a range of exoskeleton products globally. With its operations spanning across the Americas, Germany, Poland, Europe, the Middle East, Africa, and the Asia Pacific, the company caters to both medical and industrial sectors through its two primary segments: EksoHealth and EksoWorks. The EksoHealth segment is dedicated to the medical market, providing innovative solutions for individuals with neurological or physical disabilities, while the EksoWorks segment targets the industrial domain, offering devices that enhance the productivity and safety of able-bodied users performing strenuous repetitive tasks. Founded in 2005 and headquartered in San Rafael, California, Ekso Bionics is at the forefront of wearable bionic technology, aiming to improve human mobility and efficiency through their groundbreaking products.

Products and Services

  • EksoNR
  • A cutting-edge wearable bionic suit and rehabilitation device, the EksoNR is designed to assist physical therapists and physicians in the treatment of patients suffering from acquired brain injury, stroke, and spinal cord injury. Its primary aim is to facilitate and enhance mobility and strength during the rehabilitation process, thereby accelerating patient recovery.

  • Ekso Indego Therapy
  • This adjustable, powered lower-limb exoskeleton is tailored for use in therapy settings. The Ekso Indego Therapy exoskeleton provides support and mobility for individuals undergoing rehabilitation, focusing on improving gait and independence in users with mobility impairments.

  • Ekso Indego Personal
  • As a personal use version of the therapy exoskeleton, the Ekso Indego Personal offers individuals with lower limb paralysis or weakness the opportunity to stand and walk at home and in their communities. It represents a significant step towards personal mobility and independence for individuals with mobility challenges.

  • Ekso Nomad
  • The Ekso Nomad is a power knee ankle foot orthosis designed to offer dynamic support for individuals requiring assistance with lower-limb mobility. It integrates seamlessly into the user’s life, providing a more natural gait pattern and empowering users in their daily activities.

  • Ekso EV
  • Targeting the industrial sector, the Ekso EV is a wearable upper body exoskeleton that supports and elevates a worker's arms for tasks ranging from chest height to overhead positions. This device is engineered to reduce the physical strain on workers performing repetitive tasks and thus, mitigating the risk of work-related injuries while increasing productivity.

Contact Information

Address: 1414 Harbour Way South
Phone: 510 984 1761